Literature DB >> 10789728

Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey.

D Y Wang1, D S Allen, B L De Stavola, I S Fentiman, J Brussen, R D Bulbrook, B S Thomas, J L Hayward, M J Reed.   

Abstract

Between 1961 and 1967 a cohort of over 5000 women volunteered for a prospective study to determine the relationship between the urinary androgen metabolites, androsterone (A) and aetiocholanolone (E), and risk of breast cancer. During the first 10 years of the study the concentration of urinary A and E was determined in 1887 of the urine specimens. In 1971 we reported that subnormal amounts of urinary A and E were associated with a significantly increased risk of breast cancer. The cohort has been followed regularly during the 37 years since inception of the study and, by May 1998, 248 women had been diagnosed with breast cancer. Urinary androgen metabolites had been measured in 116 of these cases. Analysis of these data confirmed that women diagnosed in the first decade of the study were more likely to have low levels of urinary androgen metabolites. In the following decades, however, those who developed breast cancer were more likely to have manifested an increased A and E excretion. The reversal in the relationship between androgen metabolite excretion and risk suggests that age, or probably more importantly, menopausal status at diagnosis is an important modifying factor. Dichotomizing at age 50 it was found that in the younger age group (predominantly premenopausal) the rate ratios in the lowest tertile of A or E excretion were two- to threefold greater than for those in the highest tertile (chi2(1) = 3.57; P = 0.06: chi2(1) = 4.70; P = 0.03 for A and E respectively). In contrast, in the older age group comprising predominantly post-menopausal women, the rate ratios associated with the lowest tertile of A or E were half that of those in the highest tertile (chi2(1) = 4.10; P = 0.04; chi2(1) = 8.72; P = 0.003 for A and E respectively). This suggests that there may be different endocrine promotional factors for pre-and post-menopausal breast cancer. Hormonal risk factors may vary during the lifetime of an individual woman and this may have profound consequences for prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789728      PMCID: PMC2363403          DOI: 10.1054/bjoc.1999.1180

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

Review 1.  Endogenous estrogen and postmenopausal breast cancer: a quantitative review.

Authors:  H V Thomas; G K Reeves; T J Key
Journal:  Cancer Causes Control       Date:  1997-11       Impact factor: 2.506

2.  Plasma testosterone and breast cancer.

Authors:  P Hill; L Garbaczewski; F Kasumi
Journal:  Eur J Cancer Clin Oncol       Date:  1985-10

3.  Endocrine status in normal British, Japanese and Hawaiian-Japanese women.

Authors:  J L Hayward; F C Greenwood; G Glober; G Stemmerman; R D Bulbrook; D Y Wang; S Kumaokas
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

4.  Actions and interactions of delta 5-androstene-3 beta, 17 beta-diol and 17 beta-estradiol in the immature rat uterus.

Authors:  L G van Doorn; J Poortman; J H Thijssen; F Schwarz
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

Review 5.  Abnormal production of androgens in women with breast cancer.

Authors:  G Secreto; B Zumoff
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

6.  Chloromethyldimethylsilyl ethers in the routine assay of urinary 11-deoxy-17-oxosteroids by gas-liquid chromatography.

Authors:  B S Thomas; D R Walton
Journal:  J Endocrinol       Date:  1968-06       Impact factor: 4.286

7.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

Authors:  U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

Review 8.  The discriminant-function test: a marker of Th1/Th2 cell cytokine secretion and breast tumour oestrogen synthesis.

Authors:  M J Reed
Journal:  Mol Med Today       Date:  1995-05

9.  A prospective study of urinary oestrogen excretion and breast cancer risk.

Authors:  T J Key; D Y Wang; J B Brown; C Hermon; D S Allen; J W Moore; R D Bulbrook; I S Fentiman; M C Pike
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

10.  Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.

Authors:  G Secreto; C Recchione; A Cavalleri; M Miraglia; V Dati
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

View more
  9 in total

1.  Androgen-dependent regulation of human MUC1 mucin expression.

Authors:  Stephen Mitchell; Paul Abel; Sanjeev Madaan; James Jeffs; Khurram Chaudhary; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

Review 2.  Linking Physical Activity to Breast Cancer via Sex Steroid Hormones, Part 2: The Effect of Sex Steroid Hormones on Breast Cancer Risk.

Authors:  Ann E Drummond; Christopher T V Swain; Kristy A Brown; Suzanne C Dixon-Suen; Leonessa Boing; Eline H van Roekel; Melissa M Moore; Tom R Gaunt; Roger L Milne; Dallas R English; Richard M Martin; Sarah J Lewis; Brigid M Lynch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-10-20       Impact factor: 4.254

3.  Objective habitual physical activity and estradiol levels in obese Latina adolescents.

Authors:  Lauren E Gyllenhammer; Amanda K Vanni; Courtney E Byrd-Williams; Marc Kalan; Leslie Bernstein; Jaimie N Davis
Journal:  J Phys Act Health       Date:  2012-10-04

4.  gamma-Glutamyl transferase and breast cancer risk.

Authors:  I S Fentiman; D S Allen
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

Review 5.  Post-menopausal breast cancer: from estrogen to androgen receptor.

Authors:  Avisek Majumder; Mahavir Singh; Suresh C Tyagi
Journal:  Oncotarget       Date:  2017-10-27

6.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

Review 7.  Environmental pollutants and breast cancer.

Authors:  Julia Green Brody; Ruthann A Rudel
Journal:  Environ Health Perspect       Date:  2003-06       Impact factor: 9.031

8.  The Steroid Metabolome and Breast Cancer Risk in Women with a Family History of Breast Cancer: The Novel Role of Adrenal Androgens and Glucocorticoids.

Authors:  Lauren C Houghton; Renata E Howland; Ying Wei; Xinran Ma; Rebecca D Kehm; Wendy K Chung; Jeanine M Genkinger; Regina M Santella; Michaela F Hartmann; Stefan A Wudy; Mary Beth Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-30       Impact factor: 4.090

9.  Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women.

Authors:  Mariana Chavez-MacGregor; Carla H van Gils; Yvonne T van der Schouw; Evelyn Monninkhof; Paulus A H van Noord; Petra H M Peeters
Journal:  Breast Cancer Res Treat       Date:  2007-05-22       Impact factor: 4.872

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.